Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproic acid and lenvatinib in recurrent and/or metastatic adenoid cystic carcinoma
2026-525733-24-00Phase 2Authorised
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lenvatinib and valproic acid in adenoid cystic carcinoma (ACC), sponsored by ASST Spedali Civili di Brescia. Primary endpoints: Change in quality of life and Overall response rate. Planned start Aug 2026; status: authorised.
02
Drugs
lenvatinibvalproic acid
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on 2026-525733-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525733-24-00.